UCB in licensing pact with Novartis for German market

08/24/2009 | Reuters

UCB licensed in commercial rights to blood pressure drugs Dafiro and Dafiro HCT and agreed to extend its rights to heart drug Provas in Germany beyond 2011 under a deal with Novartis. "With this agreement, we are building on our strengths in Germany, our excellent position in the internal medicine segment," a UCB executive said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC